IP Library Granted Patent US 6,914,050
Granted Patent B2
US 6,914,050 · App. 09/909,122 · Granted Jul 5, 2005

Stimulation of bone growth with thrombin peptide derivatives

Assignee: The Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,914,050
App. No.
09/909,122
Granted
Jul 5, 2005
Kind
B2
Abstract

Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.

Claims (23)

1. A method of stimulating bone growth in a subject at a site in need of bone growth and at which bone growth would not occur at said site if left untreated, said method comprising the step of administering to the site a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor, wherein said agonist is a polypeptide of between 12 and 23 amino acids in length and is represented by the following structural formula:

Arg-Gly-Asp-Ala-R,

wherein Asp-Ala-R is a seine esterase conserved sequence.

2. The method of claim 1 , wherein R comprises the amino acid sequence Cys-X 1 -Gly-Asp-Ser-Gly-Gly-Pro-X 2 -Val (SEQ ID NO: 2), wherein X 1 is Glu or Gln and X 2 is Phe, Met, Leu, His or Val.

3. The method of claim 2 , wherein the subject is a farm animal, a companion animal or a laboratory animal.

4. The method of claim 1 , wherein the site is in need of a bone graft.

5. The method of claim 1 , wherein the site is a segmental gap in a bone, a bone void or at a non-union fracture.

6. The method of claim 1 , wherein the peptide comprises a C-terminal amide.

7. The method of claim 6 , wherein the peptide comprises the amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 5).

8. The method of claim 7 , wherein the agonist is administered in a pharmaceutical composition additionally comprising an implantable, biocompatible carrier.

9. The method of claim 9 , wherein the implantable, biocompatible carrier is an osteoconductive matrix.

10. The method of claim 7 , wherein the carrier comprises a polylactic acid/polyglycolic acid homopolymer or copolymer.

11. The method of claim 1 , wherein the peptide comprises the amino acid sequence Arg-Gly-Asp-Ala-Cys-X 1 -Gly-Asp-Ser-Gly-Gly-Pro-X 2 -Val (SEQ ID NO: 4), wherein X 1 is Glu or Gln and X 2 is Phe, Met, Leu, His or Val.

12. The method of claim 1 , wherein the C-terminus of the peptide is unsubstituted.

13. A method of stimulating bone growth in a subject at a site in need of bone growth and at which bone growth would not occur at said site if left untreated, said method comprising the step of administering to the site a therapeutically effective amount of a peptide of 23 amino acids in length comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 5).

14. The method of claim 13 wherein the peptide is C-terminal amidated.

15. The method of claim 13 , wherein the peptide is Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 5).

16. A method of stimulating bone growth in a subject at a site in need of a bone graft, said method comprising the step of administering to the site a therapeutically effective amount of a C-terminal amidated peptide of 23 amino acids comprising the sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 6).

17. A method of stimulating bone growth in a subject at a segmental bone gap, a bone void or a non-union fracture, said method comprising the step of administering to the bone gap, bone void or nonunion fracture, a therapeutically effective amount of a C-terminal amidated peptide of 23 amino acids comprising the sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 6).

18. A method of stimulating bone growth in a subject at an ectopic site in need of bone growth and at which bone growth would not occur at said ectopic site if left untreated, said method comprising the step of administering to the ectopic site a therapeutically effective amount of a C-terminal amidated peptide of 23 amino acids comprising the sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO: 6).

19. A method of stimulating bone growth in a subject at a site in need of bone growth and at which bone growth would not occur at said site if left untreated, said method comprising the step of administering to the site a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor, wherein said agonist is a polypeptide of 23 amino acids in length and is represented by the following structural formula:

Arg-Gly-Asp-Ala-R,

wherein Asp-Ala-R is a serine esterase conserved sequence.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2011
From: CAPSTONE THERAPEUTICS CORP.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 026804/0615 →
CHANGE OF NAME Recorded Aug 8, 2011
From: ORTHOLOGIC CORP.
To: CAPSTONE THERAPEUTICS CORP.
Reel/Frame 026715/0031 →
CONFIRMATION OF ASSIGNMENT (INCORPORATING COPY OF ASSIGNMENT WITH APPENDIX A) Recorded Feb 3, 2006
From: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
To: ORTHOLOGIC CORP.
Reel/Frame 017519/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2005
From: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE
To: ORTHOLOGIC CORP.
Reel/Frame 016945/0272 →
MEMORANDUM OF EXCLUSIVE LICENSE W/EXHIBIT Recorded Aug 5, 2004
From: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE
To: CHRYSALIS BIOTECHNOLOGY, INC.
Reel/Frame 015044/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2001
From: CARNEY, DARRELL H.; CROWTHER, ROGER S.; SIMMONS, DAVID J.; YANG, JINPING; REDIN, WILLIAM R.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,THE
Reel/Frame 012017/0290 →
Continuity (2)
Provisional Application 6021930000 · Jul 19, 2000
Related Publication 20020128202A1 · Sep 12, 2002